CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-07). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.7.
Verdict No. 2349 · Search date 2026-08-07 · Methodology v0.7

Pulsed electromagnetic-field device,
does it really help with Improvement of insomnia symptoms?

30-Second Summary
C
Evidence Grade C · 50 · Safety acceptable
Patient-reported insomnia improved, but evidence comes from one short manufacturer-funded trial
No severe adverse events occurred during four weeks, and reported events were mostly mild. Long-term and special-population safety remain unestablished.
What the
research shows
The grade is C. In a 153-participant multicenter double-blind randomized trial, week-4 Insomnia Severity Index scores were 7.13 with the active device and 11.07 with sham. The reported between-group effect reached Cohen d 0.86. The manufacturer funded the study and supplied the device, while the trial was under 200 participants, lasted four weeks, and measured no objective treatment outcome.
What the
ads claim
Verdict 1386 is D with 34 points for knee osteoarthritis; this verdict concerns insomnia symptoms. Results from different indications were not combined merely because both use the PEMF label.
*

Useful facts when choosing a product

  • The system generated 1-Hz pulses under the head and used a wrist monitor algorithm to stop stimulation after sleep onset.
  • The paper states: “This study is sponsored by BestCare & SuMian BioTech Co., Ltd., who also provided the PMTS.”
  • The authors declared no potential conflicts and stated that the sponsor had no role in analysis, interpretation, or scientific writing.
Gap Measurement · Verdict 2349 · C 50
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Liao and colleagues randomized 153 adults at three sleep centers to active PMTS, 76 participants, or sham, 77 participants. The study included one baseline week, four treatment weeks, and one follow-up week. Sham emitted mild heat but no magnetic field. The primary outcome was weekly patient-reported ISI; secondary outcomes were PSQI and sleep-diary latency, efficiency, actual sleep time, and wake after sleep onset. No actigraphy or treatment-effect polysomnography was included. Missing values were multiply imputed.

02

Why this is classified as C (50)

Moderate-to-large patient-reported effects came from a 153-participant, four-week manufacturer-funded trial, giving C with 50 points.

Counterpoint. Objective sleep effects and long-term durability remain unconfirmed.

Rejudgment record. Cross-check applied — Moderate-to-large patient-reported effects versus sham, limited by manufacturer funding, small sample, and short duration

Scoring profile behind this grade
EndpointPPatient-reported treatment goal - the symptom is the goal
ReplicationR1Single confirmatory trial
IndependenceI0Evidence comes only from manufacturer studies
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improvement in patient-reported insomnia symptomsCBetween-group ISI and PSQI effects were moderate to large, but evidence is manufacturer-only.
Improvement in actigraphy or polysomnography sleep outcomes?The pivotal PMTS trial did not measure efficacy with objective sleep testing.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Multicenter double-blind randomized sham-controlled trial77BestCare & SuMian BioTech Co., Ltd. sponsored the study and provided the PMTSWeekly ISI primary outcome; PSQI and sleep-diary secondary outcomesWeek-4 ISI 7.13±0.50 versus 11.07±0.51; the article did not define the type of the ± values. Reported between-group d 0.86, P<0.001. PSQI between-group d 0.58.Pivotal direct randomized trial
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-07).

Liao J, Wang S, Zhou B, et al. Efficacy and Safety of Pulse Magnetic Therapy System in Insomnia Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Psychiatry Investig. 2023;20(6):559-566. PMID: 37357671. PMCID: PMC10307909. DOI: 10.30773/pi.2022.0362.
checked
Anderson DJ, Troxel WM, Landvatter J, Baron KG. A randomized pilot study of a wearable device using variable complex weak magnetic fields among participants with insomnia symptoms. J Clin Sleep Med. 2025;21(7):1285-1291. PMID: 40165746. PMCID: PMC12225276. DOI: 10.5664/jcsm.11692.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-07 · Corrections: none

Cite this verdict

Pulsed electromagnetic-field device x insomnia Evidence Grade C card
[Chamgap] Pulsed electromagnetic-field device x insomnia — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/pulsed-electromagnetic-field-device-insomnia/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.